



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/699,635	
			Filing Date	October 30, 2003	
			First Named Inventor	William G. Tatton	
			Art Unit	1646	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	IFM-005CP4CN2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
Z-F	A1	4,861,800	08-29-1989	Buyske	
Z-F	A2	5,242,950	09-07-1993	Fries Hastings	
Z-F	A3	5,276,057	01-04-1994	Milgram, et al.	
Z-F	A4	5,322,859	06-21-1994	Schoenwald, et al.	
Z-F	A5	5,444,095	08-22-1995	Tatton, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
Z-F	A6	WO 85/05617 A1	12-19-1985	Chinoin Gyogyszer		
Z-F	A7	WO 88/04552 A1	06-30-1988	Chinoin Gyogyszer		
Z-F	A8	CA 1,329,132	12-09-1988	Somerset Pharmaceuticals		
Z-F	A9	WO 90/01928 A1	03-08-1990	Chinoin Gyogyszer		
Z-F	A10	EP 0 473 252 A2	03-04-1992	Deprenyl Animal Health		
Z-F	A11	WO 92/17169 A1	10-15-1992	University of Toronto		
Z-F	A12	WO 92/21333 A2	12-10-1992	Pharmavene, Inc.		
Z-F	A13	WO 93/12775 A1	07-08-1993	Chinoin Gyogyszer		
Z-F	A14	WO 95/11016 A1	04-27-1995	Teva Pharmaceutical Ind.		
Z-F	A15	WO 96/22068 A2	07-25-1996	Somerset Pharmaceuticals		
Z-F	A16	WO 96/26720 A1	09-06-1996	R.P. Scherer Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Z-F	A17	Ariens, E. "Stereochemistry: A Source of Problems in Medicinal Chemistry," <i>Medicinal Research Reviews</i> 6(4): 451-66 (1986)	
Z-F	A18	Birkmayer, W. et al. "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar® Treatment in Parkinson's Disease: A Longterm Study" <i>J. Neural Transmission</i> 64:113-127 (1985)	
Z-F	A19	Buys, Y.M. et al., "Deprenyl Rescues Retinal Ganglion Layer Cells After Optic Nerve Crush", <i>Investigative Ophthalmology & Visual Science</i> 35(4):1484, Abstract No. 1062 (1994)	

Examiner Signature	<i>Zachary Fay</i>	Date Considered	10/16/05
-----------------------	--------------------	--------------------	----------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/699,635	
			Filing Date	October 30, 2003	
			First Named Inventor	William G. Tatton	
			Art Unit	1646	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	IFM-005CP4CN2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2.f	B1	Greenwood, Carol E. et al. "Increased Dopamine Synthesis in Aging Substantia Nigra Neurons" <i>Neurobiology of Aging</i> 12:557-565 (1991)	
2.f	B2	Heinonen, E.H. "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects" <i>Neurology</i> , A156, No. 19P (1993)	
2.f	B3	Jonakait, G. Miller et al. "Development of serotonin, substance P and thyrotrophin-releasing hormone in mouse medullary raphe grown in organotypic tissue culture: developmental regulation by serotonin" <i>Brain Research</i> 473:336-343 (1988)	
2.f	B4	Knoll, J. "The Facilitation of Dopaminergic Activity in the Aged Brain by (-)Deprenyl A Proposal for a Strategy to Improve the Quality of Life in Senescence" <i>Mechanisms of Aging and Development</i> 30:109-122 (1983)	
2.f	B5	Magyar, K. "Behaviour of (-)-deprenyl and its analogues" <i>J. Neural Transm. Suppl.</i> 41:167-175 (1994)	
2.f	B6	Mehra, K. et al. "Pargyline Drops in Glaucoma" <i>Arch Ophthalmol.</i> 92(6):453-454 (1974)	
2.f	B7	The Merck Index, 10th edition, Windholz, M. (Ed.), Abstract 2893, p. 423, Abstract 6988, p. 1023, Abstract 1983; p. 282 (1983)	
2.f	B8	Nickel, B. "Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats" <i>J. Neural Transm. Suppl.</i> 32:139-144 (1990)	
2.f	B9	Rao, T.S. "N,N-Dipropargyl-2-Phenylethylamine, A Potential Prodrug of 2-Phenylethylamine: Neurochemical and Neuropharmacological Studies in Rat" <i>Brain Research Bulletin</i> 19: 47-55 (1987)	
2.f	B10	Riederer, P. and Youdim, M. "Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with (-)-Deprenyl" <i>Journal of Neurochemistry</i> 46:1359-65 (1986)	
2.f	B11	Rinne, "Nigral degeneration in Parkinson's disease in relation to clinical features" <i>Acta Neurol Scand.</i> 84, Suppl. 136:87-90 (1991)	
2.f	B12	Rinne, et al. "Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease" <i>Neurology</i> 41:859-861(1991)	
2.f	B13	Seniuk et al. "Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP" <i>Brain Res.</i> 527(1):7-20 (1990)	
2.f	B14	Tatton et al. "Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson's Disease" <i>Can. J. Neurological Sciences</i> 19:124-133 (1992)	
2.f	B15	Tatton et al. "Different Rates of Age-Related Loss For Four Murine Monoaminergic Neuronal Populations" <i>Neurobiol. of Aging</i> 12: 543-556 (1991)	
2.f	B16	Tatton et al. "MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells" <i>Brain Res.</i> 527(1): 21-31(1990)	

Examiner Signature	<i>Robert F. Fox</i>	Date Considered	10/16/05
--------------------	----------------------	-----------------	----------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/699,635		
		Filing Date	October 30, 2003		
		First Named Inventor	William G. Tatton		
		Art Unit	1646		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	3	Attorney Docket Number	IFM-005CP4CN2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Z-f	C1	Timar, Julia "Recovery of Mao-B Enzyme Activity After (-)Deprenyl (Selegiline) Pretreatment, Measured In Vivo" <i>Acta Physiologica Hungarica</i> 74(3-4):259-266 (1989)	
Z-f	C2	Torok, Tamas L. et al. "Transmitter releasing action of selegiline ((-)-deprenyl) from peripheral sympathetic nerves under different experimental conditions" <i>J. Pharm. Pharmacol.</i> 39(10):797-802 (abstract of pp. 48 of Chemical Abstracts) (1987)	
Z-f	C3	Trope, G.Z. et al. "Deprenyl Improves Visual Function in Glaucoma Patients," <i>Investigative Ophthalmology & Visual Science</i> 35(4):2178, Abstract No. 4270-40 (1994)	
Z-f	C4	Zsilla, Gabriella et al. "Neurochemical evidences for facilitation of dopaminergic function in rat brain by repeated doses of (-) deprenyl" <i>Dev. Neurosci. (Amsterdam; 17 (Regular Transm. Funct.: Basic Clin. Aspects))</i> ; Abstract of pp. 345-348; pp. 64 of Chemical Abstracts (1984)	
Z-f	C5	Zsilla, Gabriella et al. "The Effect of Repeated Doses of (-) Deprenyl On The Dynamics of Monoaminergic Transmission. Comparison With Clorgyline" <i>Pol. J. Pharmacol. Pharm.</i> 38:57-67 (1986)	
Z-f	C6	Zsilla, Gabriella et al. "(-)-Deprenyl A Selective Mao 'B' Inhibitor Increases [³ H]imipramine Binding And Decreases β -Adrenergic Receptor Function" <i>European J. of Pharmacol.</i> 89:111-117 (1983)	
Z-f	C7	Zsilla, G. and Knoll, J. "The Action of (-)Deprenyl on Monoamine Turnover Rate in Rat Brain" <i>Typical and Atypical Antidepressants: Molecular Mechanisms</i> pp. 211-217 (1982)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Zohrab Fay</i>	Date Considered	10/16/05
--------------------	-------------------	-----------------	----------